Charles River Laboratories International Partners With Magellan Stem Cells For Development, Clinical Advancement Of Stem Cell-Based Therapies, Regenerative Medicine Solutions
Charles River Laboratories International, Inc. (NYSE: CRL) and Magellan Stem Cells, a private Australian biotech and cell-therapy firm, announce their collaboration to support Magellan in the development and clinical
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga